Form 4: BioXcel CEO Vimal Mehta Executes RSU Vesting and Tax Sale

CEO Vimal Mehta acquired 49,758 shares via RSU vesting and sold 19,419 shares to cover tax obligations.

Summary

• CEO Vimal Mehta acquired 49,758 shares of common stock on May 4, 2026, following the vesting of Restricted Stock Units (RSUs).
• On May 20, 2026, the CEO sold 19,419 shares at a weighted average price of $1.087 per share.
• The sale was conducted under a Rule 10b5-1 trading plan specifically to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, the CEO maintains a direct beneficial ownership of 69,598 shares, in addition to indirect holdings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a discretionary market move.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to equity management.
• The sale was limited to the amount necessary to cover tax liabilities, suggesting the CEO retains a significant portion of the vested equity.

Negatives

• The sale price of $1.087 reflects the current low trading value of the company's common stock.

Risks

• Continued reliance on equity-based compensation for executive retention.
• Market volatility impacting the value of the CEO's remaining holdings.

Future Outlook

The remaining 149,274 unvested RSUs are scheduled to vest in three equal installments of 25% on the last day of each subsequent six-month period, subject to continued employment.

Management Comments

• The reporting person confirms the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 3, 2026, solely to cover taxes due.

Industry Context

StockSavvy.ai notes that executive stock sales for tax purposes are standard industry practice and generally do not signal a lack of confidence in the company's long-term prospects, especially when executed under pre-established 10b5-1 plans.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a best-practice standard for corporate executives to avoid potential insider trading concerns.
• The retention of a significant portion of vested shares (approx. 61%) is consistent with executive alignment with shareholder interests.

Related Party Transactions

• The reporting person is an executive officer and board member of BioXcel Holdings, Inc. and BioXcel LLC, and may be deemed a beneficial owner of securities held by BioXcel LLC.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and limited to tax coverage.

Next Steps

• Future vesting of remaining 149,274 RSUs in three equal installments.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Insider Trading, Form 4, Vimal Mehta, Equity Compensation, Rule 10b5-1